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1  |  INTRODUCTION
Endothelium- derived C- type natriuretic peptide (CNP) pos-
sesses cytoprotective and anti- atherogenic functions that 
regulate vascular homeostasis.[1–3] The vasoprotective ef-
fects of CNP are mediated, at least in part, by natriuretic 
peptide receptor type- C (NPR- C), which is widely thought 
to function as a systemic clearance receptor, removing natri-
uretic peptides from the circulation through internalization 
and degradation.[4,5]
C- type natriuretic peptide produces vascular smooth 
muscle (SM) relaxation via NPR- C agonism, stimulating 
Gi protein and G- protein- coupled inwardly rectifying po-
tassium channels (GIRKs), resulting in hyperpolarization 
(Figure 1).[6] Furthermore, administration of small molecule 
NPR- C agonists exerts a dose- dependent hypotension in 
vivo.[1]
Despite sophisticated in vivo characterization of the mod-
ulatory effects of CNP and a handful of small molecule ag-
onists on NPR- C, no practical and robust screening cascade 
exists to identify and characterize more potent, bioavailable 
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Abstract
Endothelium- derived C- type natriuretic peptide possesses cytoprotective and anti- 
atherogenic functions that regulate vascular homeostasis. The vasoprotective effects 
of C- type natriuretic peptide are somewhat mediated by the natriuretic peptide recep-
tor C, suggesting that this receptor represents a novel therapeutic target for the treat-
ment of cardiovascular diseases. In order to facilitate our drug discovery efforts, we 
have optimized an array of biophysical methods including surface plasmon reso-
nance, fluorescence polarization and thermal shift assays to aid in the design, assess-
ment and characterization of small molecule agonist interactions with natriuretic 
peptide receptors. Assay conditions are investigated to explore the feasibility and 
dynamic range of each method, and peptide- based agonists and antagonists are used 
as controls to validate these conditions. Once established, each technique was com-
pared and contrasted with respect to their drug discovery utility. We foresee that such 
techniques will facilitate the discovery and development of potential therapeutic 
agents for NPR- C and other large extracellular domain membrane receptors.
K E Y W O R D S
biophysical, CNP, fluorescence polarization, NPR-C, surface plasmon resonance, thermal shift
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original 
work is properly cited.
© 2018 The Authors. Chemical Biology & Drug Design Published by John Wiley & Sons Ltd
2 |   CONOLE Et aL.
small molecule NPR- C agonists in vitro. In this work, we uti-
lize biophysical assays such as surface plasmon resonance,[9] 
fluorescence polarization[10] and thermal shift[11] to establish 
and optimize a reliable in vitro screening platform to allow 
NPR- C receptor ligands to be identified, selected and ranked 
for more advanced functional in vivo assays.
2 |  METHODS AND MATERIALS
2.1 | Materials
The selective NPR- C antagonist M372049[12] (WuXi AppTec, 
China) and CNP (Sigma- Aldrich, UK) were obtained commer-
cially. Dual NPR- A and NPR- C ligand PL- 3994 was a gift from 
the Hobbs Lab at QMUL.[13] Human full- length (FL) NPR- C 
(27–541)- 10His- Flag (GenBank accession: NM_000908) 
and extracellular domain (ECD) NPR- C (27–481)- 6His were 
expressed and isolated at Peak Proteins, UK. The fluores-
cent reporter molecule, 5- carboxyfluorescein N- terminus la-
belled GLSKG[CFGRSLDRIGSLSGLGC]NS (Flu- P19), 
GLSKG(CFVNVSQDRIGSQSGLGC)NS (Flu- P20) and 
GLSKG(CFGRSLDRIGSLSGSGC)TQDS (Flu- P21) were 
obtained commercially (Peptide Protein Research Ltd, UK). 
The Protein Thermal Shift™ Dye Kit was obtained commer-
cially (Thermo Fisher Scientific, UK).
2.2 | Protein characterization and 
oligomer status
Conditions for full- length NPR- C sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS- PAGE): Novex 
Wedgewell 10%–20% Tris- Glycine 12 well (Invitrogen 
XP00102); markers: RunBlue prestained tricolour marker, 
Expedion NXA6050, 4 μl loaded (MW); either 4, 2 or 1 μg 
protein loaded under reducing (R) or non- reducing (NR) 
conditions. Conditions for extracellular NPR- C SDS- 
PAGE: Novex Wedgewell 10%–20% Tris- Glycine 12 well 
(Invitrogen XP00102); markers: RunBlue prestained tri-
colour marker, Expedion NXA6050, 5 μl loaded; either 
3 or 5 μg protein loaded under reducing or non- reducing 
conditions.
2.3 | Surface plasmon resonance
All SPR analysis was performed on a BIAcore T200 sys-
tem using Series S CM5 sensor chips. All sensorgrams 
were double- referenced by subtracting the response on 
a reference flow cell and a blank sample. Ligands were 
evaluated against both the FL (27–541) and ECD (27–481) 
of NPR- C. Human FL NPR- C (27–541)- 10His- Flag and 
ECD NPR- C (27–481)- 6His were covalently attached to 
a CM5 chip via amine coupling[14] with a surface density 
of 10,000 RU and 5,000 RU, respectively. Single- cycle 
sequential injections of CNP (0.5–8 nM) were performed 
at a flow rate of 30 μl/min (240 s for each), followed by a 
dissociation time of 3,600 s. Binding of M372049 (0.23–
500 nM) and PL- 3994 (8.3 pM–500 nM) was analysed by 
multi-cycle sequential injections (90- s association time 
for both M372049 and PL- 3994) followed by undisturbed 
dissociation (240 s for both M372049 and PL- 3994), dur-
ing which curves returned to baseline. Peptide stocks were 
dissolved in dimethyl sulfoxide (DMSO), and the final 
sample solutions for kinetic affinity experiments contained 
1% DMSO in 1× phosphate- buffered saline P20 buffer 
(PBS- P, Cat no 28995084, GE Healthcare Ltd.). DMSO 
solvent effects were corrected for with eight calibration 
solutions (0.5%–1.8% DMSO in PBS- P). Equilibrium 
constants (KD) were calculated using either kinetic or 
affinity models, assuming simple 1:1 (Langmuir) bind-
ing. Data processing and analysis were performed using 
BIAevaluation and OriginPro software. The theoretical 
Rmax (the maximal feasible signal between a ligand–ana-
lyte pair) for each compound/protein pair was calculated 
using Equation (1):[14]
where Rligand, amount of protein loaded in the SPR chip in 
response units; Mranalyte, molecular weight of the compound 
of interest; Mrligand, molecular weight of the immobilized 
protein; Vligand, stoichiometry of the binding interaction 
between the ligand and the analyte.
The experimentally observed Rmax was then calculated 
as a percentage of the theoretical Rmax as a quality control 
measure. An experimental Rmax <100% of the theoretical 








F I G U R E  1  Schematic representation of the key cell signalling 
activities of natriuretic peptide receptor C (NPR- C) activation.[7] 
C- type natriuretic peptide binds the NPR- C receptor and causes 
a conformational change that allows Giα to bind and then inhibit 
adenylate cyclase enzyme. Similarly, NPR- C may modulate 
phospholipase Cβ via the βγ subunit.[8] Gi protein activation also 
produces vascular smooth muscle relaxation through interaction with 
G- protein- coupled inwardly rectifying potassium channels
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2.4 | Fluorescence polarization
All experiments were performed using HEPES buffer, an 
80 μl final volume and 3% DMSO. Protein titration ex-
periments (0.12–500 nM) were performed at 15 nM probe 
concentration, selected with guidance from in- house SPR 
analysis and the literature Ki of the untagged P19 pep-
tide.[15] To achieve a balance of protein consumption and 
fluorescence polarization dynamic read- out range for com-
petition experiments, the concentrations selected for FL 
and extracellular NPR- C proteins were 150 and 400 nM. 
Keeping the appropriate reaction plate or tubes on ice, the 
optimized fluorescence polarization samples were prepared 
in the following order—ligand in HEPES buffer (CNP 
or M372049, 20 μl), NPR- C protein (600 nM, FL, 20 μl, 
or 1,600 nM, ECD, 20 μl) in HEPES buffer and Flu- P19 
probe (30 nM, 40 μl) in HEPES buffer. Fluorescence polar-
ization competition experiments against the Flu- P19 probe 
were performed with varying concentrations (4.89 nM–
2.5 μM) of each CNP and M372049 and their fluorescence 
polarization read- out measured and normalized to experi-
ment controls (buffer + probe, buffer + probe + protein) 
using a BMG Labtech Omega Pherastar® plate reader 
(filter settings: 485 nm [excitation] and 520 nm [emis-
sion]). Background fluorescence polarization was blanked 
using a HEPES buffer- only control. Raw data were pro-
cessed using OriginPro curve fitting software to obtain the 
IC50s. A web- based IC50- to- Ki converter that computes Ki 
values from experimentally determined IC50 values was 
employed.[16]
2.5 | Thermal shift
Thermal shift assays were performed using Thermo Fisher 
Scientific Protein Thermal Shift™ Dye Kit, and samples were 
prepared according to the accompanying protocol.[17] A so-
lution of Protein Thermal Shift™ Dye was always prepared 
fresh from the 1,000× stock. Optimization experiments were 
performed by titrating NPR- C protein (0.1, 0.05 and 0.01 mg/
ml) and Protein Thermal Shift™ Dye concentration (80, 8 and 
1×) to identify conditions that achieved melt curves with the 
greatest dynamic fluorescence range and least standard error 
in Tm (melt temperature) values. Keeping the reaction plate 
on ice, the optimized protein melt reactions were prepared in 
the following order—Protein Thermal Shift™ Buffer (5.0 μl), 
water + FL NPR- C (0.45 mg/ml stock, 4.44 μl) + buffer or 
ligand (CNP, M372049, PL- 3994, 1:1 or 10:1 stoichiometric 
ratios with the protein, 12.5 μl) and Diluted Protein Thermal 
Shift™ Dye (8× stock 2.5 μl). The total volume for each reac-
tion was 20.0 μl. Each melt reaction was mixed at least 10 
times, and the plate was sealed with MicroAmp® Optical 
Adhesive Film. The plate was then spun it at 112 g for 1 min 
and placed on ice until measurement. Thermal melt reactions 
were performed and analysed using a 7500 Real- Time PCR 
System®. A 5- carboxy- X- rhodamine (ROX) reporter and a 
continuous temperature ramp of 25–99°C were used (2 min 
per step). Optical filters were set at 580 nm (excitation) and 
623 nm (emission). The Tm for each sample was obtained 
by differentiating the original fluorescence melt curve using 
OriginPro mathematical and peak identification functions. 
The reported Tm values are the mean across four replicates.
F I G U R E  2  Reducing and non- reducing sodium dodecyl sulphate polyacrylamide gel electrophoresis for full- length natriuretic peptide 
receptor C (NPR- C) (a) (27–541) and extracellular domain NPR- C (b) (27–481)
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3 |  RESULTS
3.1 | Protein characterization and oligomer 
status
Non- reducing SDS- PAGE analyses of the protein batches 
used in these experiments indicated that FL NPR- C was 
primarily present as the active disulphide- bonded dimer 
(~130 kDa), whereas the ECD mainly existed as the mono-
mer (~55 kDa; Figure 2).
3.2 | Surface plasmon resonance
To validate the integrity of the NPR- C protein and commer-
cial peptides in our hands, SPR analyses of CNP and pepti-
domimetic NPR- C antagonist M372049 were conducted and 
compared to that in the literature.[1] Another NPR- C bind-
ing peptide PL- 3994 was also evaluated, and all three KD 
F I G U R E  3  Single- cycle kinetics (0.5–8 nM, 5 concentrations) 
experiment with C- type natriuretic peptide against full- length natriuretic 
peptide receptor C (27–541). Ka (1/Ms) is the association constant, and 
Kd (1/s) is the dissociation constant—the KD is calculated from these 
parameters using the Langmuir 1:1 binding model (see Section 2 for 
further details)
F I G U R E  4  Representative raw sensorgrams for M372049 (a) and PL- 3994 (b). Natriuretic peptide receptor C (NPR- C) peptide binders. KD 
values (equilibrium constants) were calculated using the kinetic (Langmuir 1:1) model. Representative steady- state affinity curves for M372049 (C) 
and PL- 3994 (d) NPR- C peptide binders. KD values (equilibrium constants) were derived from a Michaelis–Menten model, which best fits the data
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values were in agreement with the literature binding data [13] 
(Figures 3 and 4). CNP was evaluated using a single- cycle ki-
netic run, due to its picomolar binding (Figure 3) preventing 
equilibrium binding analysis. Affinity curves for M372049 
and PL- 3994 multi- cycle runs exhibited sigmoidal curve 
shape and sensical Rmax values, suggesting genuine NPR- C 
binding saturation (Figure 4, Table 1).[18] To illustrate the re-
liability of the protocol in our hands, peptide controls were 
run at least twice and were shown to be reproducible. We 
were interested to evaluate whether there was any difference 
in ligand binding between the dimeric FL and monomeric 
ECD immobilized NPR- C. Interestingly, very similar data 
were obtained (Table 1).
3.3 | Fluorescence polarization
Using phage display methodology, Deschênes et al.[15] 
identified potent and selective peptide antagonists of NPR- 
B. It was also discovered that a number of these peptides, 
termed P19, P20 and P21, displayed competitive inhibi-
tion of NPR- C against radiolabelled 125I- ANP in at least 
the nanomolar range.[15] We postulated that one of these 
peptides may be a reasonable starting point to synthesize 
a fluorescent reporter molecule and commissioned the 
syntheses of their corresponding 5- carboxyfluorescein N- 
terminus tagged derivatives (Figure 5). Steady- state af-
finity SPR analysis of the Flu- P19 probe demonstrated a 
KD ~ 10 nM against FL NPR- C (Figure 6). Based on this 
information and FP guidelines,[10] we conducted a protein 
titration experiment at 15 nM Flu- P19 probe concentration. 
The results exhibited a sigmoidal relationship, and to 
achieve a balance of protein consumption and FP dynamic 
read- out range, an NPR- C protein concentration of 150 nM 
was selected for competitive inhibition experiments with 
our three positive controls (Figure 7). While similar ex-
periments were performed with the P20- and P21- tagged 
peptides, only minimal fluorescence polarization windows 
could be obtained (data not shown).
Competition experiments with CNP and M372049 
elicited IC50 values of 141.7 and 190.7 nM, respectively 
(Figure 8). Using optimized conditions, these experiments 
were also demonstrated to be reproducible across different 
days (Table 2). Evaluation of these ligands with the ECD 
of NPR- C yielded similar results (Table 2). An important 
parameter to determine the robustness of a competition in-
hibition assay is the inhibition constant (Ki). Using kinetic 
equations,[16] Ki’s (competitive) of 0.49 and 3.7 nM were cal-

































Notes. FL: full length; ECD: extracellular domain; His: histidine; KD: equilibrium constant as calculated by ei-
ther steady- state affinity or kinetic methods; % theoretical Rmax: experimentally measured percentage of the 
maximal feasible signal between a ligand–analyte pair.
T A B L E  1  Summary of reproducibility 
of control peptide SPR analysis
F I G U R E  5  Peptide sequence and fluorophore structure of 
5- carboxyfluorescein N- terminus labelled probes P19, P20 and P21
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(within 1–1.5 log concentration units) with that in the litera-
ture (Table 2).[13,19]
3.4 | Thermal shift
To our current knowledge, there is no literature for the de-
termination of NPR- C binding by thermal shift. This bio-
physical technique could serve as a useful orthogonal assay 
for confirmation of binding particularly for small molecules 
that bind non- competitively with CNP- like peptides. Using 
a commercial thermal shift assay kit, an assay condition 
 optimization experiment was conducted and demonstrated 
that concentrations of 0.1 mg/ml of NPR- C protein and 1× 
fluorescent dye produced consistent melt curves and accurate 
calculation of the NPR- C Tm value (Figure 9a,b).
Using concentrations of CNP and M372049 as recom-
mended by the literature[11] and based on our optimized 
protein concentration, the effect of ligand treatment on 
NPR- C Tm was investigated. Each of the peptide controls 
shifted the Tm by significant amounts, and the peptide ag-
onist CNP gave a pronounced shift ΔTm ~11°C, whereas 
the antagonist M372049 gave a shift of ΔTm ~2.5°C 
(Figure 9c,d).
4 |  DISCUSSION
Isolated G- protein- coupled receptors (GPCRs) are notori-
ously difficult to interrogate, as their active conformation is 
usually dependent on being supported in a membrane con-
text.[21] Characterization of NPR- C binding in three distinct 
biophysical assays demonstrates that it is indeed possible to 
evaluate GPCRs without the need for complex membrane 
structure surrogates, such as nanodiscs.[22–24] It should be 
noted however that NPR- C is an atypical GPCR in that it 
lacks a seven transmembrane domain, and ~90% of this pro-
tein is extracellular.[25–28] These methods may not only be 
applicable for GPCRs but for other dissimilar receptors that 
possess a large and well- defined ECD.[29] We have shown 
this to be the case in the application of biophysical screening 
techniques for discovery of neuropilin- 1 ligands, an immuno-
globulin domain protein receptor for the vascular endothelial 
growth factor (VEGF).[30–32]
The higher prevalence of the FL NPR- C dimer compared 
with the ECD could be attributed to the proximity of the di-
sulphide bond to the membrane.[33] For the ECD, this sug-
gested that only ~25% of the molecules are held together by 
disulphide bonds, and the non covalent dimers fell apart into 
monomers on the reducing SDS- PAGE. This could have been 
F I G U R E  6  SPR raw sensorgram (a) and affinity curve (b) for Flu- P19 binding to full length natriuretic peptide receptor C
F I G U R E  7  Titration of full- length natriuretic peptide receptor 
C protein against a fixed concentration (15 nM) of Flu- P19 probe. 
The protein concentration selected was 150 nM
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anticipated, as the structural information on the FL NPR- C 
shows extensive non  covalent interactions contributing to the 
formation of the dimer.[34] Interestingly, all three peptide li-
gands demonstrated similar binding kinetics for the FL and 
ECD NPR- C, suggesting that the dimer formation is not nec-
essarily required for active site binding.
The surface plasmon resonance analysis of the three 
peptides displayed highly sensitive binding detection, with 
distinct responses above the baseline observed at concen-
trations as low as 1 nM (Figures 3 and 4). It was interest-
ing to observe that both dimeric FL and monomeric ECD 
NPR- C possess similar properties with respect to the bind-
ing of ligands tested in this study. This suggests that surface 
plasmon resonance could be a useful tool for interrogating 
mutant NPR- C proteins to gain further understanding of key 
binding residues. While surface plasmon resonance pro-
vides high information content, its sequential run operation 
somewhat limits its utility as a high- throughput screen, at 
least when measuring concentration–response curves. In 
contrast, once a 384- well fluorescence polarization plate 
has been prepared, spectroscopic read- out of the entire 
plate takes place in a matter of minutes, suggesting this 
technique is more amenable to high- throughput compound 
screening. The fluorescence polarization technique is lim-
ited, however, to interrogate molecules that compete with 
the reporter molecule for the orthosteric binding site, and 
so this particular assay set- up would not be able to identify 
non- competitive, allosteric modulators. In order to remedy 
this, an FP probe would need to be designed to bind at the 
identified allosteric site of interest, and while this would be 
challenging for this particular project, it has been achieved 
with other examples.[35,36] The thermal shift technique is 
equally amenable to high throughput, as plate reading takes 
only just over an hour; however, this technique is rather 
protein- intensive and thus more expensive. The full contrast 
and comparison of the three biophysical methods compared 
with traditional radiolabelled ligand binding studies are out-
lined in Table 3. The choice of the most appropriate screen-
ing cascade will depend on the structural class and binding 
mode of the small molecules of interest. We propose that a 
combination of either surface plasmon resonance or fluores-
cence polarization as a primary screen, followed by a ther-
mal shift assay to confirm binding, would function well as a 
mechanism to identify NPR- C ligands that could go forward 
into more advanced functional in vivo assays to characterize 
agonists or antagonists.
F I G U R E  8  Representative fluorescence polarization competition experiments and calculated IC50 values between the fluorescently tagged 
Flu- P19 peptide (15 nM) and natriuretic peptide receptor C peptide ligands C- type natriuretic peptide (a) and M372049 (b)






CNP (27–541)- 10His 
(FL)







M372049 (27–541)- 10His 
(FL)





Notes. Ki values were calculated using a web- based IC50- to- Ki converter from 
experimentally determined IC50 values and compared to that in the literature.[16]
FL: full length; ECD: extracellular domain.
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F I G U R E  9  Raw (a) and differentiated (b) full length (FL) natriuretic peptide receptor C (NPR- C) protein melt curves. Derivatized 
(differentiated) FL NPR- C protein melt curves for increasing concentrations of agonist C- type natriuretic peptide (c) and antagonist M372049 (b)
T A B L E  3  A contrast and comparison of three modern biophysical binding assays with respect to their utility in drug discovery compared 
with traditional radiolabelled ligand binding assays
Biophysical method Advantages Disadvantages
Surface plasmon resonance • High information content—binding constants 
(affinity and kinetics) can be determined
• Can evaluate multiple proteins binding 
simultaneously
• Minimal protein required
• Highly sensitive
• Standard BIAcore machine is expensive, 
though cheaper alternatives may exist
• Medium throughput
• Cost of some consumables is high 
(microchips)
• Susceptible to false positives
Fluorescence polarization • High throughput
• Can determine EC50/Ki values for compound 
ranking
• Detection of inhibitors that are allosteric 
require bespoke FP probe design and 
synthesis
Thermal Shift • High throughput
• Cheap
• Less susceptible to false positives
• High protein concentration required
• False negatives
Traditional radiolabelled ligand binding 
assay
• Highly sensitive • Uses hazardous materials
• Labour intensive (multiple washing steps)
• Expensive
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5 |  CONCLUSIONS
We have established three biophysical methods and a frame-
work to discover and characterize novel ligands of NPR- C, 
an important protein for vascular homeostasis. Some of these 
methods are high throughput and can be adapted for library 
screening, whereas others could serve as an orthogonal bio-
physical technique. We foresee that such techniques will fa-
cilitate the discovery and development of potential therapeutic 
agents for cardiovascular diseases, and other extracellular 
membrane targets.
ACKNOWLEDGMENTS
This work was funded by a translational award from the 
British Heart Foundation (TG/15/3/31692), Wellcome Trust 
grants (084449/Z/07/Z and 078496/Z/05/Z), UCL Business 
PLC (PoC- 12- 007) and an Apollo Therapeutics one- off ex-
periment fund.
CONFLICT OF INTEREST
DC, SM and FM declare that they have no conflict of 
interest. AH and DS are named inventors on a patent 
(EP3145914A1) covering the composition of novel NPR- C 
agonists. Through the university revenue- sharing scheme, 
inventors may, should the invention ever be commercial-
ized, and in the fullness of time, receive some financial 
benefit.
ORCID
Daniel Conole  http://orcid.org/0000-0002-3389-8377 
REFERENCES
 [1] A. J. Moyes, R. S. Khambata, I. Villar, K. J. Bubb, R. S. Baliga, 
N. G. Lumsden, F. Xiao, P. J. Gane, A. S. Rebstock, R. J. 
Worthington, M. I. Simone, F. Mota, F. Rivilla, S. Vallejo, C. 
Peiró, C. F. Sánchez Ferrer, S. Djordjevic, M. J. Caulfield, R. J. 
MacAllister, D. L. Selwood, A. Ahluwalia, A. J. Hobbs, J. Clin. 
Invest. 2014, 124, 4039. 
 [2] K. Nakao, K. Kuwahara, T. Nishikimi, Y. Nakagawa, H. 
Kinoshita, T. Minami, Y. Kuwabara, C. Yamada, Y. Yamada, 
T. Tokudome, C. Nagai-Okatani, N. Minamino, Y. M. Nakao, 
S. Yasuno, K. Ueshima, M. Sone, T. Kimura, K. Kangawa, K. 
Nakao, Hypertension 2017, 69, 286.
 [3] B. Pressure, P. Eder-negrin, R. H. Adams, H. A. Baba,  Circulation 
2018, 138, 494. https://doi.org/10.1161/CIRCULATIONAHA. 
117.033383
 [4] T. Maack, M. Suzuki, F. A. Almeida, D. Nussenzveig, R. M. 
Scarborough, G. A. McEnroe, J. A. Lewicki, Science (80- .) 1987, 
238, 675.
 [5] T. Maack, Kidney Int. 1996, 49, 1732.
 [6] S. D. Chauhan, H. Nilsson, A. Ahluwalia, A. J. Hobbs, Proc. Natl 
Acad. Sci. USA 2003, 100, 1426.
 [7] R. A. Rose, W. R. Giles, J. Physiol. 2008, 586, 353.
 [8] M. B. Anand-Srivastava, Peptides 2005, 26, 1044.
 [9] S. G. Patching, Biochim. Biophys. Acta - Biomembr. 2014, 1838, 
43.
 [10] N. J. Moerke, Curr. Protoc. Chem. Biol. 2009, 1, 1.
 [11] M. Vivoli, H. R. Novak, J. A. Littlechild, N. J. Harmer, J. Vis. 
Exp. 2014, 91, 1.
 [12] I. C. Villar, C. M. Panayiotou, A. Sheraz, M. Madhani, R. S. 
Scotland, M. Nobles, B. Kemp-Harper, A. Ahluwalia, A. J. 
Hobbs, Cardiovasc. Res. 2007, 74, 515.
 [13] J. D. Edelson, M. Makhlina, K. R. Silvester, S. S. Vengurlekar, X. 
Chen, J. Zhang, C. J. Koziol-White, P. R. Cooper, T. J. Hallam, 
D. W. Hay, R. A. Panettieri Jr, Pulm. Pharmacol. Ther. 2013, 26, 
229.
 [14] A. B. Biacore, E. July, A. B. Biacore, BIAevaluation Software 
Handbook (3rd ed), Biacore AB, Uppsala, 1997.
 [15] J. Deschênes, C. Duperé, N. McNicoll, N. L’Heureux, F. Auger, 
A. Fournier, A. De Léan, Peptides 2005, 26, 517.
 [16] R. Z. Cer, U. Mudunuri, R. Stephens, F. J. Lebeda, Nucleic Acids 
Res. 2009, 37, 441.
 [17] Applied Biosystems, Protein Thermal Shift ™ Studies, Life 
Technologies, Carlsbad, CA 2011.
 [18] A. M. Giannetti, B. D. Koch, M. F. Browner, J. Med. Chem. 2008, 
51, 574.
 [19] C. A. Veale, V. C. Alford, D. Aharony, D. L. Banville, R. A. 
Bialecki, F. J. Brown, J. R. Damewood Jr, C. L. Dantzman, P. D. 
Edwards, R. T. Jacobs, R. C. Mauger, M. M. Murphy, W. Palmer, 
K. K. Pine, W. L. Rumsey, L. E. Garcia-Davenport, A. Shaw, G. 
B. Steelman, J. M. Surian, E. P. Vacek, Bioorg. Med. Chem. Lett. 
2000, 10, 1949.
 [20] F. J. Moya, J. A. De Juan, A. Ripodas, R. Bernal, A. Fernandez-
Cruz, R. Fernandez-Durango, Vision. Res. 1998, 38, 3833.
 [21] W. R. Leifert, G Protein-Coupled Receptors in Drug Discovery, 
Humana Press, New York City, NY, 2015, Vol. 552.
 [22] S. Locatelli-Hoops, A. A. Yeliseev, K. Gawrisch, I. Gorshkova, 
Biomed. Spectrosc. Imaging 2013, 2, 155.
 [23] C. Yoshiura, Y. Kofuku, T. Ueda, Y. Mase, M. Yokogawa, M. 
Osawa, Y. Terashima, K. Matsushima, I. Shimada, J. Am. Chem. 
Soc. 2010, 132, 6768.
 [24] N. Bocquet, J. Kohler, M. N. Hug, E. A. Kusznir, A. C. Rufer, 
R. J. Dawson, M. Hennig, A. Ruf, W. Huber, S. Huber, Biochim. 
Biophys. Acta - Biomembr. 2015, 1848, 1224.
 [25] L. Birnbaumer, Cell 1992, 71, 1069.
 [26] L. Birnbaumer, J. Abramowitz, A. M. Brown, Biochim. Biophys. 
Acta 1990, 1031, 163.
 [27] M. B. Anand-Srivastava, P. D. Sehl, D. G. Lowe, J. Biol. Chem. 
1996, 271, 19324.
 [28] F. Fuller, J. G. Porter, A. E. Arfsten, J. Miller, J. W. Schilling, 
R. M. Scarborough, J. A. Lewicki, D. B. Schenk, J. Biol. Chem. 
1988, 263, 9395.
 [29] L. R. Potter, A. R. Yoder, D. R. Flora, L. K. Antos, D. M. Dickey, 
2009, 191, 341.
 [30] F. Mota, C. Fotinou, R. R. Rana, A. W. E. Chan, T. Yelland, M. 
T. Arooz, A. P. O’Leary, J. Hutton, P. Frankel, I. Zachary, D. 
Selwood, S. Djordjevic, FEBS J. 2018, 285, 1290.
 [31] J. Powell, F. Mota, D. Steadman, C. Soudy, J. T. Miyauchi, S. 
Crosby, A. Jarvis, T. Reisinger, N. Winfield, G. Evans, A. 
10 |   CONOLE Et aL.
Finniear, T. Yelland, Y. T. Chou, A. W. E. Chan, A. O’Leary, L. 
Cheng, D. Liu, C. Fotinou, C. Milagre, J. F. Martin, H. Jia, P. 
Frankel, S. Djordjevic, S. E. Tsirka, I. C. Zachary, D. L. Selwood, 
J. Med. Chem. 2018, 61, 4135.
 [32] H. Jia, R. Aqil, L. Cheng, C. Chapman, S. Shaikh, A. Jarvis, A. W. 
Chan, B. Hartzoulakis, I. M. Evans, A. Frolov, J. Martin, P. Frankel, 
S. Djordevic, I. C. Zachary, D. L. Selwood, ChemBioChem 2014, 
15, 1161.
 [33] M. Itakura, M. Iwashina, T. Mizuno, T. Ito, H. Hagiwara, S. 
Hirose, J. Biol. Chem. 1994, 269, 8314.
 [34] X. He, A. Dukkipati, K. C. Garcia, J. Mol. Biol. 2006, 361, 698.
 [35] K. G. Harikumar, E. E. Cawston, L. J. Miller, Assay Drug Dev. 
Technol. 2011, 9, 394.
 [36] P. Grover, H. Shi, M. Baumgartner, C. J. Camacho, T. E. 
Smithgall, PLoS ONE 2015, 10, 1.
How to cite this article: Conole D, Myers SH, Mota 
F, Hobbs AJ, Selwood DL. Biophysical screening 
methods for extracellular domain peptide receptors, 
application to natriuretic peptide receptor C ligands. 
Chem Biol Drug Des. 2018;00:1–10.  
https://doi.org/10.1111/cbdd.13395
